Catalent has completed the $1.2 billion acquisition of Paragon Bioservices, a leading viral vector development and manufacturing partner for gene therapies.   With the addition of Paragon’s specialized expertise in adeno-associated virus (AAV) vectors, the most commonly used vector to deliver DNA to cells, Catalent is positioned to capitalize on strong industry tailwinds in the potentially $40 billion addressable market for gene therapies. Paragon also brings to Catalent its unique and different...